Quick Answer
LISATA THERAPEUTICS, INC. reported Total Revenue of $170.0 thousand for fiscal year 2025.
LISATA THERAPEUTICS, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $170.0K -83.0% |
$1.00M | $0.00 | — | — | — |
| Revenue (ASC 606) | $170.0K -83.0% |
$1.00M | $0.00 | — | — | — |
| Net Income | -$16.59M +17.0% |
-$19.98M +4.1% |
-$20.84M +61.6% |
-$54.23M -97.4% |
-$27.47M -237.0% |
-$8.15M +57.9% |
| Diluted EPS | -$1.91 +20.4% |
-$2.40 +7.0% |
-$2.58 +75.4% |
-$10.47 -40.5% |
-$7.45 -1305.7% |
-$0.53 |
| Total Assets | $17.74M -49.3% |
$35.00M -36.0% |
$54.69M -25.1% |
$73.03M -24.7% |
$97.01M +169.5% |
$36.00M +32.6% |
| Cash and Equivalents | $15.96M -1.6% |
$16.21M -28.3% |
$22.59M -29.7% |
$32.15M +30.5% |
$24.65M +49.3% |
$16.51M +17.7% |
| Long-Term Debt | — | — | — | — | — | — |
| Stockholders Equity | $14.86M -49.8% |
$29.57M -38.6% |
$48.15M -27.7% |
$66.58M -27.8% |
$92.25M +183.9% |
$32.50M +56.1% |
| R&D Expense | — | — | — | — | $17.68M +91.1% |
$9.25M -14.3% |
| Operating Income | -$18.21M +18.7% |
-$22.41M +12.8% |
-$25.71M +55.4% |
-$57.60M -98.3% |
-$29.05M -51.7% |
-$19.14M +4.7% |
| Gross Profit | — | — | — | — | — | — |
| Shares Outstanding | 8.83M +5.1% |
8.41M +3.2% |
8.15M +3.6% |
7.87M +97.3% |
3.99M -79.4% |
19.38M +84.2% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $0.00 | — | -100.0% |
| Revenue (ASC 606) | September 30, 2025 | $0.00 | — | -100.0% |
| Net Income | September 30, 2025 | -$4.25M | +13.8% | +8.8% |
| Diluted EPS | September 30, 2025 | -$0.49 | +16.9% | +9.3% |
| Total Assets | September 30, 2025 | $21.76M | -43.0% | -13.5% |
| Cash and Equivalents | September 30, 2025 | $19.00M | -2.6% | +12.8% |
| Long-Term Debt | September 30, 2017 | $0.00 | -100.0% | — |
| Stockholders Equity | September 30, 2025 | $17.37M | -48.4% | -17.4% |
| R&D Expense | June 30, 2022 | $3.24M | -25.2% | -1.2% |
| Operating Income | September 30, 2025 | -$4.41M | +17.3% | +9.3% |
| Gross Profit | September 30, 2013 | $731.0K | +6.5% | +487.7% |
| Shares Outstanding | September 30, 2025 | 8.76M | +5.2% | +1.5% |
- LISATA THERAPEUTICS, INC. reported Total Revenue of $170.0 thousand for fiscal year 2025.
- LISATA THERAPEUTICS, INC. showed a decrease of -83.0% in Total Revenue compared to the prior fiscal year.
- LISATA THERAPEUTICS, INC. reported Revenue (ASC 606) of $170.0 thousand for fiscal year 2025.
- LISATA THERAPEUTICS, INC. showed a decrease of -83.0% in Revenue (ASC 606) compared to the prior fiscal year.
- LISATA THERAPEUTICS, INC. reported Net Income of -$16.59 million for fiscal year 2025.
- LISATA THERAPEUTICS, INC. showed an increase of +17.0% in Net Income compared to the prior fiscal year.
- LISATA THERAPEUTICS, INC. reported Diluted EPS of $1.91 per share (loss) for fiscal year 2025.
- LISATA THERAPEUTICS, INC. showed an increase of +20.4% in Diluted EPS compared to the prior fiscal year.
- LISATA THERAPEUTICS, INC. reported Total Assets of $17.74 million for fiscal year 2025.
- LISATA THERAPEUTICS, INC. showed a decrease of -49.3% in Total Assets compared to the prior fiscal year.
- LISATA THERAPEUTICS, INC. reported Cash and Equivalents of $15.96 million for fiscal year 2025.
- LISATA THERAPEUTICS, INC. showed a decrease of -1.6% in Cash and Equivalents compared to the prior fiscal year.
- LISATA THERAPEUTICS, INC. reported Long-Term Debt of $0.00 for fiscal year 2017.
- LISATA THERAPEUTICS, INC. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- LISATA THERAPEUTICS, INC. reported Stockholders Equity of $14.86 million for fiscal year 2025.
- LISATA THERAPEUTICS, INC. showed a decrease of -49.8% in Stockholders Equity compared to the prior fiscal year.
- LISATA THERAPEUTICS, INC. reported R&D Expense of $17.68 million for fiscal year 2021.
- LISATA THERAPEUTICS, INC. showed an increase of +91.1% in R&D Expense compared to the prior fiscal year.
- LISATA THERAPEUTICS, INC. reported Operating Income of -$18.21 million for fiscal year 2025.
- LISATA THERAPEUTICS, INC. showed an increase of +18.7% in Operating Income compared to the prior fiscal year.
- LISATA THERAPEUTICS, INC. reported Gross Profit of $1.72 million for fiscal year 2013.
- LISATA THERAPEUTICS, INC. showed a decrease of -27.7% in Gross Profit compared to the prior fiscal year.
- LISATA THERAPEUTICS, INC. reported Shares Outstanding of 8.83 million shares for fiscal year 2025.
- LISATA THERAPEUTICS, INC. showed an increase of +5.1% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: